prikaz prve stranice dokumenta Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
  Preuzmi
PDF 16.71 MB
Znanstveni rad - Izvorni znanstveni rad
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
Biomedicines, 9 (2021), 11; 1547. https://doi.org/10.3390/biomedicines9111547
Japjec, Mladen; Horvat Pavlov, Katarina; Petrovic, Andreja; Staresinic, Mario; Sebecic, Bozidar; Buljan, Matko; Vranes, Hrvoje; Giljanovic, Ana; Drmic, Domagoj; Japjec, Miroslav; Prtoric, Andreja; Lovric, Eva; Batelja Vuletic, Lovorka; Dobric, Ivan; Boban Blagaic, Alenka; Skrtic, Anita; Seiwerth, Sven; Predrag, Sikiric Više autora...

Citiranost:
,
Citirajte ovaj rad

Japjec, M., Horvat Pavlov, K., Petrovic, A., Staresinic, M., Sebecic, B., Buljan, M. ... Predrag, S. (2021). Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines, 9. (11), 1547. doi: 10.3390/biomedicines9111547

Japjec, Mladen, et al. "Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats." Biomedicines, vol. 9, br. 11, 2021, str. 1547. https://doi.org/10.3390/biomedicines9111547

Japjec, Mladen, Katarina Horvat Pavlov, Andreja Petrovic, Mario Staresinic, Bozidar Sebecic, Matko Buljan, Hrvoje Vranes, et al. "Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats." Biomedicines 9, br. 11 (2021): 1547. https://doi.org/10.3390/biomedicines9111547

Japjec, M., et al. (2021) 'Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats', Biomedicines, 9(11), str. 1547. doi: 10.3390/biomedicines9111547

Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, i sur.. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines [Internet]. 27.10.2021. [pristupljeno 02.04.2025.];9(11):1547. doi: 10.3390/biomedicines9111547

M. Japjec, et al., "Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats", Biomedicines, vol. 9, br. 11, str. 1547, Listopad 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:264:862164. [Citirano: 02.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:264:862164
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
AutorMladen Japjec
AutorKatarina Horvat Pavlov
AutorAndreja Petrovic
AutorMario Staresinic
AutorBozidar Sebecic
AutorMatko Buljan
AutorHrvoje Vranes
AutorAna Giljanovic
AutorDomagoj Drmic
AutorMiroslav Japjec
AutorAndreja Prtoric
AutorEva Lovric
AutorLovorka Batelja Vuletic
AutorIvan Dobric
AutorAlenka Boban Blagaic
AutorAnita Skrtic
AutorSven Seiwerth
AutorSikiric Predrag
Autorova ustanova(Klinička bolnica Merkur)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
(1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels... Više in the myotendinous junctions. BPC 157 (10 µg/kg, 10 ng/kg) regimen was given (i) intraperitoneally, first application immediately after surgery, last 24 h before sacrifice; (ii) per-orally, in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat/day), till the sacrifice at 7, 14, 28 and 42 postoperative days. (3) Results: These BPC 157 regimens document prominent therapy effects (macro/microscopic, biomechanical, functional much like eNOS and COX-2 mRNA levels and counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation. Especially, in rats with the disabled myotendinous junction, along with full functional recovery, BPC 157 counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal. Accordingly, unlike the perilous course in controls, those rats, when receiving BPC 157 therapy, exhibit a smaller defect, and finally defects completely disappear. Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days. (4) Conclusions: BPC 157 restores myotendinous junction in accordance with the healing of the transected muscle, tendon, and ligament. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 9, br. 11, str. 1547
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines9111547
URN:NBNurn:nbn:hr:264:862164
Datum objave publikacije2021-10-27
URL dokumentahttps://www.mdpi.com/2227-9059/9/11/1547
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-12-23 09:31:50
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.